NCT00665600View on ClinicalTrials.gov

Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Levalbuterol HCl

Levalbuterol 0.63 TID

DRUG

Levalbuterol HCl

Levabuterol 1.25 mg TID

DRUG

Albuterol Sulfate

Racemic albuterol 2.5 mg TID

DRUG

Placebo

Placebo TID

Trial Locations (24)

Unknown

Carmichael

Spring Valley

Wheat Ridge

Largo

Miami

Panama City

Atlanta

Elk Grove Village

Hines

Wheaton

Springfield

Cadillac

Columbia

Missoula

Springfield

Chapel Hill

Mogadore

Providence

Austin

San Antonio

Calgary

Winnepeg

Mississauga

Toronto

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00665600 - Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter